{"DataElement":{"publicId":"2201010","version":"1","preferredName":"Nonsteroidal Antiandrogen Therapy Administered Type","preferredDefinition":"the type of nonsteroidal antiandrogen therapy administered.","longName":"NSAA_TX_ADM_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2201008","version":"1","preferredName":"Nonsteroidal Antiandrogen Therapy Administered","preferredDefinition":"related to the use of drugs intended to reduce serum levels of male sex hormones by blocking production or interfering with their action for therapeutic purposes.","longName":"NSAA_TX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2585605","version":"1","preferredName":"Nonsteroidal antiandrogen Therapy","preferredDefinition":"No Value Exists:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"CL316360:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nonsteroidal antiandrogen","conceptCode":"CL316360","definition":"No Value Exists","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26B1B236-A787-6606-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-10","endDate":null,"createdBy":"PWEST","dateCreated":"2007-01-10","modifiedBy":"ONEDATA","dateModified":"2007-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1FA6AF5-57E6-4E4E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Qualifier to Object Class term was missing; added 1/10/07","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2201011","version":"1","preferredName":"Nonsteroidal Antiandrogen Therapy Administered Type","preferredDefinition":"the type of nonsteroidal antiandrogen therapy administered.","longName":"NSAA_TX_ADM_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Flutamide","valueDescription":"FLUTAMIDE","ValueMeaning":{"publicId":"2561412","version":"1","preferredName":"FLUTAMIDE","longName":"2561412","preferredDefinition":"FLUTAMIDE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flutamide","conceptCode":"C509","definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCF1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F20CD46F-5B60-418F-E034-0003BA3F9857","beginDate":"2002-07-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Bicalutamide","valueDescription":"Bicalutamide","ValueMeaning":{"publicId":"2573403","version":"1","preferredName":"Bicalutamide","longName":"2573403","preferredDefinition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bicalutamide","conceptCode":"C1599","definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F20CD46F-5B64-418F-E034-0003BA3F9857","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Nilutamide","valueDescription":"Nilutamide","ValueMeaning":{"publicId":"2573402","version":"1","preferredName":"Nilutamide","longName":"2573402","preferredDefinition":"A drug that blocks the effects of male hormones in the body. It is a type of antiandrogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilutamide","conceptCode":"C1173","definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F20CD46F-5B68-418F-E034-0003BA3F9857","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Ketonconazole","valueDescription":"Ketonconazole","ValueMeaning":{"publicId":"2573401","version":"1","preferredName":"Ketonconazole","longName":"2573401","preferredDefinition":"Ketonconazole","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"CAMPBELB","dateModified":"2005-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F20CD46F-5B6C-418F-E034-0003BA3F9857","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F20CEB94-8C6A-47E0-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If yes, then select the follo","type":"Preferred Question Text","description":"If yes, then select the following","url":null,"context":"CTEP"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F20CD055-CF74-418B-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}